Vivani Medical, Inc. ( (VANI) ) has released its Q2 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vivani Medical, Inc. is a biopharmaceutical company specializing in the development of miniaturized, ultra long-acting drug implants, primarily targeting chronic diseases such as obesity and type 2 diabetes. The company has recently announced a $10 million equity financing to accelerate the development of its semaglutide implant, NPM-139, following promising preclinical and clinical study results. Vivani’s financial results for the second quarter of 2025 showed a net loss of $7.1 million, with increased research and development expenses contributing to the loss. The company is also planning to spin off its division, Cortigent, Inc., as an independent publicly traded entity. Looking ahead, Vivani aims to initiate clinical development of NPM-139 in 2026, with a focus on advancing its pipeline of drug implants to provide innovative therapeutic solutions for chronic conditions.